University Hospital of Old Age Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
Swiss Institute for Translational and Entrepreneurial Medicine, Bern, Switzerland.
J Alzheimers Dis. 2023;93(1):107-124. doi: 10.3233/JAD-221001.
Preclinical Alzheimer's disease (AD) is one possible cause of subjective cognitive decline (SCD). Normal task performance despite ongoing neurodegeneration is typically considered as neuronal compensation, which is reflected by greater neuronal activity. Compensatory brain activity has been observed in frontal as well as parietal regions in SCD, but data are scarce, especially outside the memory domain.
To investigate potential compensatory activity in SCD. Such compensatory activity is particularly expected in participants where blood-based biomarkers indicated amyloid positivity as this implies preclinical AD.
52 participants with SCD (mean age: 71.00±5.70) underwent structural and functional neuroimaging (fMRI), targeting episodic memory and spatial abilities, and a neuropsychological assessment. The estimation of amyloid positivity was based on plasma amyloid-β and phosphorylated tau (pTau181) measures.
Our fMRI analyses of the spatial abilities task did not indicate compensation, with only three voxels exceeding an uncorrected threshold at p < 0.001. This finding was not replicated in a subset of 23 biomarker positive individuals.
Our results do not provide conclusive evidence for compensatory brain activity in SCD. It is possible that neuronal compensation does not manifest at such an early stage as SCD. Alternatively, it is possible that our sample size was too small or that compensatory activity may be too heterogeneous to be detected by group-level statistics. Interventions based on the individual fMRI signal should therefore be explored.
临床前阿尔茨海默病(AD)是主观认知下降(SCD)的一个可能原因。尽管神经退行性变持续存在,但正常的任务表现通常被认为是神经元代偿,这反映了更大的神经元活动。在 SCD 中,已经观察到额区和顶区的代偿性脑活动,但数据很少,特别是在记忆领域之外。
研究 SCD 中的潜在代偿性活动。在基于血液的生物标志物表明淀粉样蛋白阳性的参与者中,这种代偿性活动尤其有望出现,因为这意味着存在临床前 AD。
52 名 SCD 参与者(平均年龄:71.00±5.70)接受了结构和功能神经影像学(fMRI)检查,针对情景记忆和空间能力,并进行了神经心理学评估。淀粉样蛋白阳性的估计是基于血浆淀粉样蛋白-β和磷酸化 tau(pTau181)测量值。
我们对空间能力任务的 fMRI 分析并未表明存在代偿,只有三个体素在未校正的 p<0.001 阈值下超过。在 23 名生物标志物阳性个体的亚组中,这一发现并未得到复制。
我们的结果没有提供 SCD 中代偿性脑活动的确凿证据。可能是 SCD 处于如此早期阶段,神经元代偿尚未显现。或者,可能是我们的样本量太小,或者代偿性活动过于异质,无法通过组水平统计检测到。因此,应该探索基于个体 fMRI 信号的干预措施。